Tecartus (brexucabtagene autoleucel)

pCPA File Number: 22340

Negotiation Status:

Concluded with an LOI

Indication(s):

Acute lymphoblastic leukemia (ALL), B-cell precursor, in adult patients, relapsed or refractory

Sponsor/Manufacturer:

Gilead Sciences Canada Inc.

CDA-AMC Project Number:

PG0304-000

pCPA Engagement Letter Issued:

2023-05-19

Negotiation Process Concluded:

2023-10-27